Document is current
Any future updates will be listed below
-
Authors
Cypris, Olivia
Eipel, Monika
Franzen, Julia
Rösseler, Corinna
Tharmapalan, Vithurithra
Kuo, Chao-Chung
Vieri, Margherita
Nikolić, Miloš
Kirschner, Martin
Brümmendorf, Tim H.
Zenke, Martin
Lampert, Angelika
Beier, Fabian
Wagner, Wolfgang https://orcid.org/0000-0002-1971-3217
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (WA 1706/8-1, WA 1706/12-1, BR 1782/5-1, LA 2740/3-1, 363055819/GRK2415)
Interdisziplinäres Zentrum für klinische Forschung der medizinischen Fakultät der RWTH Aachen (O3-3)
Deutsche Krebshilfe (TRACK-AML)
Bundesministerium für Bildung und Forschung (VIP+ project "Epi-Blood-Count")
- License Information
-
More Information
Article History
Received: 2 March 2020
Accepted: 30 July 2020
First Online: 20 August 2020
Ethics approval and consent to participate
: Blood samples were obtained from the Registry for Telomeropathies and Aplastic Syndromes of RWTH Aachen University and participating hospitals. The study was approved by the local ethic committee and all samples were taken after written consent (EK206/09).
: Not applicable
: WW and JF are involved in Cygenia GmbH () that may provide service for epigenetic signatures applied in this study. WW, FB, and THB are inventors of a patent application on <i>PRDM8</i> as a biomarker (DE 10 2015 121 969 A1 2017.06.22). Apart from this, the authors have nothing to disclose.
